Sequana Medical (SEQUA.BR)

Executive Summary

Sequana Medical is a Belgian medical device company addressing unmet needs in fluid overload management, primarily through its alfapump® system for ascites in liver disease and its investigational DSR® (Direct Sodium Removal) therapy for heart failure. The alfapump, an implantable device that automatically removes ascitic fluid, is already commercialized and provides a foundation for the company's growth. DSR is a novel, drug-free approach that directly removes sodium from the body, offering a potential breakthrough for diuretic-resistant heart failure patients. Sequana's mission is to improve outcomes and quality of life when standard diuretics fail, targeting high-morbidity conditions like liver disease, heart failure, and cancer-related fluid overload. Currently, Sequana is focused on advancing DSR through clinical development, with pivotal trials expected to read out in the near term. The alfapump continues to generate revenue and real-world evidence in the EU, but adoption remains limited due to reimbursement hurdles. Key risks include regulatory uncertainties, competitive pressures, and the capital-intensive nature of device commercialization. However, if DSR succeeds, it could address a large and underserved heart failure population, potentially transforming Sequana's market position. The company's valuation reflects a binary outcome tied to DSR's clinical success, offering significant upside balanced by development risk.

Upcoming Catalysts (preview)

• Q1 2026DSR Pivotal Trial Results in Heart Failure50% success
• Q2 2026US Regulatory Pathway Update for DSR60% success
• Q3 2026Alfapump Reimbursement Expansion in Europe40% success